Name: Lixte Biotechnology Holdings, Inc. (LIXT) Financial Statements
Creator: FinSpry

Lixte Biotechnology Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Lixte Biotechnology Holdings, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	0.73	0.90	1.35	1.74	1.22
Selling, General & Administrative	2.85	4.19	4.96	4.98	2.04
Operating Expenses	3.57	5.09	6.31	6.72	3.27
Operating Income	-3.57	-5.09	-6.31	-6.72	-3.27
Other Income/Expense
Interest Income	0.01	0.02	0.01	0.00	0.00
Interest Expense	0.00	-0.02	0.01	-0.01	0.00
Other Income/Expense	-0.01	0.00	0.00	0.00	0.00
Income
Income Before Tax	-3.59	-5.09	-6.31	-6.73	-3.26
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-3.59	-5.09	-6.31	-6.73	-3.26
Net Income - Continuous Operations	-3.59	-5.09	-6.31	-6.73	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-3.57	-5.07	-6.30	-6.72	0.00
EBIT	-3.57	-5.09	-6.30	-6.72	-3.27
Depreciation & Amortization	0.00	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-2.00	-3.00	-4.00	-5.00	-3.00
Diluted EPS	-2.00	-3.00	-4.00	-5.00	-3.00
Basic Shares Outstanding	2.25	1.92	1.58	1.35	1.13
Diluted Shares Outstanding	2.25	1.92	1.58	1.35	1.13